Houston A K, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
Diagn Microbiol Infect Dis. 1994 Jan;18(1):57-9. doi: 10.1016/0732-8893(94)90134-1.
The postantibiotic effect (PAE) was determined for two of the newer fluoroquinolones: DU-6859a and levofloxacin. All drugs (including ofloxacin control) had good PAE activity against Escherichia coli and Staphylococcus aureus. Only DU-6859a had PAE test conditions (< or = 0.5 mu/ml) that coincided with achievable clinical concentrations for all organisms tested. These data indicate that levofloxacin, like ofloxacin (PAEs, 1.0-2.9 h), could be administered once or twice daily and that the dosing of DU-6859a (PAEs, 1.6-2.4 h) might be extended to once every 24 h because of its documented PAE and its potency advantages as compared with levofloxacin and ofloxacin.
测定了两种新型氟喹诺酮类药物DU-6859a和左氧氟沙星的抗生素后效应(PAE)。所有药物(包括氧氟沙星对照药)对大肠杆菌和金黄色葡萄球菌均具有良好的PAE活性。只有DU-6859a的PAE测试条件(≤0.5μg/ml)与所有受试菌株可达到的临床浓度相符。这些数据表明,左氧氟沙星与氧氟沙星(PAE为1.0 - 2.9小时)一样,可每日给药一次或两次,并且由于DU-6859a(PAE为1.6 - 2.4小时)已证实的PAE以及与左氧氟沙星和氧氟沙星相比的效价优势,其给药频率可能延长至每24小时一次。